Anti-infective agents are a distinct class of pharmacologically important molecules that have served mankind in different capacities to combat life-threatening pathological conditions. They include antibacterial, antifungal, antiviral, antituberculosis, antimalarial, and urinary anti-infective agents. However, evolutionary changes, adaptations, and the development of new strains of pathogenic microorganisms have reduced the therapeutic efficacy of existing drugs, thus, limiting their clinical utility over the years. Frontiers in Anti-Infective Agents Volume 6 is a collection of notable research efforts, successful anti-infective drug development programs, and a comprehensive overview of successful and unsuccessful clinical trials conducted in this domain. This volume continues from the last one with interesting reviews on 1) “Reverse Vaccinology” for vaccination design using computational data to identify vaccine targets, 2) leptospirosis, 3) phage therapy for bacterial infections, 4) quorum sensing inhibitors from natural products, and 5) nitrogen and oxygen-based heterocyclic compounds that can act as anti-infective agents. The volume, therefore, covers a range of frontier topics on anti-infective research and development. This compilation is a timely reference for postgraduate scholars and researchers seeking updates in specific areas of anti-infective drug development. Allied healthcare professionals (clinical and public healthcare professionals) can also benefit from the information presented within.

Frontiers in Clinical Drug Research – Anti infectives is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of infectious diseases. The scope of the book series covers a range of topics including the chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of infectious diseases. Reviews in this series also include research on multi drug resistance and pre-clinical / clinical findings on novel antibiotics, vaccines, antifungal agents and antitubercular agents. Frontiers in Clinical Drug Research – Anti infectives is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of anti infective drug discovery and epidemiology. The sixth volume of this series features these interesting reviews: - Direct-acting antiviral drugs for treatment of Hepatitis C virus infection - Plant lattices as anti-infective compounds - Antimicrobial materials and devices for biomedical applications - Recent advances in the treatment of toxoplasmosis - Antimicrobial immunoglobulin prophylaxis and therapy - Targeting Magnesium Homeostasis as Potential Anti-Infective Strategy Against Mycobacteria

Anti-infective agents are a distinct class of pharmacologically important molecules that has served mankind in different capacities to combat life-threating pathologic conditions. They include antibacterial, antifungal, antiviral, antituberculosis, antimalarial and urinary anti-infective agents. However, evolutionary changes, adaptations and development of pathogenic microorganisms strains the therapeutic efficacy of these drugs thus limiting their clinical utility over the years. Frontiers in Anti-Infective Agents Volume 5 is a collection of notable research efforts, successful anti-infective drug development programmes and a comprehensive overview of the successes and failures of recent clinical trials in this domain. The volume covers interesting topics: 1) the treatment of acute wounds with the vikut® formula, 2) anti-infective treatment of ocular diseases and 3) sars-cov vaccine development and antimicrobial therapy for SARS symptoms. A chapter summarizing recent anti-infective approaches rounds up the contents of this volume. This volume is a timely reference for postgraduate scholars and researchers seeking updates in specific areas of anti-infective drug development. Allied healthcare professionals (clinical and public healthcare professionals) can also benefit from the information presented within.

This concise clinical reference facilitates health consultants and professionals for determining treatment options for some common prenatal and postpartum infections during pregnancy and the puerperium in patients. Key Features - Presents 9 organized, easy to read chapters on anti-infective agents for pregnant patients - Covers pharmacokinetics and pharmacodynamics of relevant anti-infective agents - Includes information on classification and safety of anti-infective agents - Includes treatment of urinary tract infections - Covers medications for sexually transmitted diseases, including a complete section dedicated to HIV medication - Provides information about vulvovaginal infections - Covers the treatment of toxoplasmosis in pregnancy - innovates with information about herbal remedies for infection for patients during pregnancy and breastfeeding Pregnancy and Anti-Infective Agents is therefore, a valuable handbook that enables quick consultation on safe antibiotics for the treatment of a variety of infections in pregnancy.

The volume is a comprehensive documentation on major infectious diseases from tropical countries which pose a serious threat to global healthcare programs. These include diseases such as tuberculosis, AIDS, leishmaniasis (kala-azar), elephantiasis, malaria, leprosy, various fungal disorders and emergent viral diseases. Due to the widespread use of antibiotics, there is an emergence of drug-resistant pathogens in many regions. Hence, there is a need to search for novel, cost-effective bioactive compounds that demonstrate high efficacy and low toxicity in human cells from unexplored ecosystems to combat emerging drug-resistant pathogens. Chapters of this volume focus on the pathogenesis and etiology of each of the mentioned diseases, updated WHO reports wherever applicable, conventional drugs and their pharmacokinetics as well as new approaches to develop anti-infective agents. The authors also present a detailed report on ‘superbugs’ (multi-drug resistant pathogens) and new measures being taken up to eradicate them. Information about new antimicrobials (bioactive peptides and silk protein sericin) and the approaches taken by scientists and healthcare professionals for successful targeting of these molecules for human medicine. This volume is essential for general readers, healthcare professionals, researchers, and academicians actively involved in research on infectious diseases and anti-infective therapeutic drugs. [Series Introduction] Frontiers in Anti-Infective Agents is a book series that focuses on current and new antibiotics and vaccines. The series highlights the challenges faced by healthcare workers around the globe when facing epidemics caused by life-threatening pathogens along with the measures being taken to combat these challenges. The series is essential reading for all involved in infectious disease research including microbiologists, medical professionals, epidemiologists, and life science researchers.

This volume of Frontiers in Anti-Infective Agents provides updates on the most recent studies about anti-infective agents, their mechanism of action, the relevant molecular targets and their implication in the development of novel antibiotics that have properties similar to their corresponding compounds of natural origin. The initial chapter covers the mode of action of natural antimycobacterial compounds such as nordihydroguaiaretic acid, α-mangostin and allicin, as well as antimicrobial peptides and their role in the innate and adaptive immune response leading to the decrease of microbial resistance. This is followed by updates on tuberculosis treatment concerning the immunological role of cells (airway epithelial cells, macrophages, neutrophils and T cells) along with their products (chemokines, cytokines) and other processes such as autophagy that influence the outcome of the host immune response to the infection. Contributors have also reviewed the latest knowledge in the cellular and molecular mechanisms that trigger a protective, immune response and the identification of the molecular targets for vaccine development, all of which are a key priority to develop control measures against Babesia species like Babesia bovis and Babesia bigemina. Additionally, the neuro-endocrine and neuro-immune mechanisms behind host responses against stress and environmental stimuli during infections are also covered in separate chapters. The volume also provides updates related to Helicobacter pylori pathogenesis. The reviews presented in Anti-infective Research and Development provide timely updates for scholars and professionals associated with the field of antimicrobial research and development.

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.